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One  hundred  and  fifty  million  people  are  infected  by 
hepatitis C virus (HCV) worldwide, and chronic hepatitis 
C is now the leading indication for liver transplantation 
in the US [1]. Transmitted principally by blood, HCV is 
passed by transfusion of inadequately screened blood and 
blood products, and by intravenous drug use; sexual and 
vertical  transmission  also  occur,  but  at  substantially 
lower  rates  than  in  other  blood-borne  viral  infections. 
Unsterile dental equipment, accidental needle punctures 
in  medical  facilities,  and  tattooing  are  also  linked  to 
transmission.  Following  acquisition  of  infection,  70  to 
85% of patients will develop persistent viremia, usually 
for the duration of their lives. Not all of these will develop 
liver failure, however - infection is often indolent for long 
periods. Nonetheless, two decades after infection about 
20% of HCV-infected subjects will have developed end-
stage liver disease [2].
Hepatitis C is now a more common cause of cirrhosis 
than alcoholism. Though chronic hepatitis is the major 
result of HCV infection, there are other manifestations of 
the  disease  that  stem  from  chronic  inflammation  and 
associated immune cell stimulation with cytokine release. 
These include arthritis, antibody-mediated thrombocyto-
penia,  itching,  porphyria  cutanea  tarda,  dermatitis, 
glomerulo  nephritis and cryoglobulinemia.
HCV is a small (50 nm) single-stranded RNA member 
of the flaviviridae family. The RNA has one open reading 
frame, preceded by a ribosome-binding site within a UTR 
(untranslated region). The open reading frame encodes a 
3,011  amino  acid  protein  that  is  cleaved  into  several 
different  proteins  by  proteases  of  viral  and  cellular 
origins. The amino acid sequences include nucleocapsid, 
envelope, protease, helicase, transmembrane, and RNA 
polymerase  proteins.  The  HCV  RNA  polymerase  is 
highly error prone, and the sequences of HCV genomes 
display  enormous  amounts  of  variation.  Six  different 
genotypes of HCV have been characterized. They differ 
from one another at nearly one-third of their nucleotide 
positions, but in practice are defined by mutations in the 
5΄UTR. These six genotypes are stable, heritable variants 
that differ in their geographic distribution. Superimposed 
on this already substantial variation is the fact that large 
numbers  of  mutations  occur  in  any  given  individual’s 
HCV  isolate  over  time  -  that  is,  as  in  HIV,  each  new 
infection  gives  rise  to  a  cloud  of  sequence  variants 
descended  from  the  original  infection;  this  cloud  is 
sometimes  referred  to  as  a  ‘quasispecies’.  This  extra-
ordinary sequence diversity renders the virus very resis-
tant  to  standard  immune  responses  and  inhibits  the 
production of a useful preventive vaccine. Thus the virus 
is very difficult to clear when infection occurs.
The  two  coat  proteins  of  the  virus  are  heavily 
glycosylated and recognize receptors on the hepatocyte. 
Though not entirely proven, these receptors are thought 
to be CD81, claudin-1 and occludin [3-5]. Virions repli-
cate at an enormous rate in hepatocytes, from which they 
are released into the blood (they may invade monocytes 
and B cells as well, but this is uncertain). The titer of virus 
in the blood may therefore provide a fairly accurate index 
of the hepatic load of virus. Recently a relatively well-
conserved sequence of the non-coding region has been 
identified, permitting the development of an inexpensive 
and highly accurate diagnostic polymerase chain reaction 
(PCR)-based blood test for the virus and its titer [6].
Treatment  of  hepatitis  C  was  unsuccessful  until 
interferon alfa was introduced in the 1980s. This protein 
activates  the  janus  kinase/signal  transducers  and 
activators of transcription (JAK/STAT) signaling pathway 
to induce the transcription of interleukins and caspases 
that  kill  viral  loaded  cells  [7],  but  the  toxicity  of  the 
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remission  rate  was  only  10  to  15%.  Particularly  poor 
results were seen in those infected with viral genotype 1, 
which  accounts  for  65%  of  US  cases  of  hepatitis  C  - 
including the bulk of Caucasian and the vast majority of 
American  Black  patients  [8].  The  addition  of  ribavirin 
brought the remission rate up to 20 to 25%, and a change 
to weekly pegylated interferon alfa further increased the 
response  rate  [9].  But  the  treatment  remains  difficult, 
with  side-effects  that  resemble  the  cytokine-releasing 
consequences of cancer chemotherapy, and the hemolytic 
anemia  induced  by  ribavirin  weakens  patients  still 
further. American patients with genotype 1 continue to 
respond less well than those with genotypes 2 and 3, but 
nonetheless a significant subset of genotype 1 carriers do 
benefit from treatment. Given the toxicities of interferon/
ribavirin, it would be very useful to be able to predict 
which patients might fall into the responder subclass.
Connected  to  this,  a  startling  advance  has  recently 
been made by Ge, Thomas and their co-workers [10,11], 
who have shown that a polymorphism in close proximity 
to  the  IL28B  gene  that  encodes  interferon  lambda  3 
predicts  both  spontaneous  clearance  of  HCV  and 
response to interferon and ribavirin treatment in geno-
type 1 hepatitis C infection. Clearance and response to 
therapy are not affected by the polymorphism in those 
with genotype 2 and 3 infections. The reasons for these 
disparities are not at all evident, since the genotypes are 
not associated with any known protein differences.
Finally,  the  treatment  of  hepatitis  C-induced  chronic 
liver  failure  with  liver  transplantation  illustrates  the 
dilemma posed by the growth of technology in medical 
care. The procedure is not curative. Indeed, all such liver 
transplants become re-infected by persistent virus, and in 
some  patients  the  march  to  secondary  cirrhosis  is 
accelerated, necessitating a second transplant. Ironically, 
alcoholic cirrhotics are routinely denied transplants in the 
current  donor-liver  shortage  because  it  is  thought  that 
their bibulous habits cannot be broken. Yet patients with 
hepatitis C receive transplants routinely, even though their 
livers are doomed to be re-infected and cirrhosis induced 
at a far faster rate than that caused by alcohol. Since the 
natural  progression  of  the  disease  takes  two  or  more 
decades,  and  since  most  patients  come  to  transplant  in 
their 50s or 60s, most do not require a second transplant 
but the costs of these decisions are massive.
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